ArticleFrontiers in immunology2025
Unveiling the neutrophil-Notch2-ISC axis: asiatic acid's therapeutic strategy in infectious colitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Balb/c mice were administered Results: Mouse colons were analyzed histologically, and transcriptomic, network pharmacology, western blotting, and immunohistochemistry investigations were performed. AA restored mucosal integrity by upregulating tight junction proteins (occludin and claudin 1) and acidic mucin granules levels, and by rescuing ISC proliferation through suppression of Notch2/Hes5/Hey1 signaling. Multiomics analyses further revealed the modulation of neutrophil chemotaxis and inflammatory pathways by AA. Strikingly, neutrophil ablation reduced the efficacy of AA, confirming that AA acts via neutrophil-mediated containment of bacterial invasion and epithelial shedding. Discussion: By revealing the neutrophil-Notch2-ISC axis as a pivotal regulator of mucosal repair, our findings show AA to be a dual-action therapeutic agent that synergizes immune containment and regenerative pathways. These findings highlight an aspect of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.